-- 根據週三提交給香港交易所的文件顯示，星創集團（HKG:0399）已獲得臨時禁令，阻止其股票暫停決定，並將申請司法覆核。 文件顯示，上市審查委員會維持了停牌決定，理由是該公司未能依照上市規則維持足夠的營運水準。 文件也顯示，上市審查委員會指出，該公司核心口服胰島素產品進展有限，其他業務缺乏規模、績效記錄或已證實的獲利能力。 此外，委員會也指出，該公司財務狀況不佳，總資產為11億港元（其中大部分為無形資產），淨流動負債為11億港元，且依賴主要股東提供資金。
Related Articles
Asia
Sanhua Intelligent Controls Q1 Profit Up 3%; Shares Rise 5%
Zhejiang Sanhua Intelligent Controls (SHE:002050) posted first-quarter attributable net profit of 927.6 million yuan, up 2.7% from 903.4 million yuan the previous year.Earnings per share declined to 0.22 yuan from 0.24 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 1.4% year over year to 7.77 billion yuan from 7.67 billion yuan.Shares of the refrigeration and air-conditioning components maker were up 5% in recent trade.
$SHE:002050
Asia
Singapore's Total Employment Expands in Q1
Singapore's total employment grew by 5,000 during the first quarter of the year, compared to 2,300 a year earlier, marking the 18th consecutive quarter of job growth, according to preliminary data from the Ministry of Manpower released Thursday.Despite the year-on-year growth, employment was down from the 17,700 growth in the previous quarter, mainly due to broad-based weakening in the labor market.Overall, unemployment rates edged up to 2.1% in March, compared to 2.0% in December 2025.Retrenchments remained low at 1.5 per 1,000 employees in Q1, unchanged from Q4, 2025.The ministry expects labor market to remain tight and expand in the second quarter. However, the share of firms expecting to hire in the next three months fell to 44.6% in March, compared to 54.6% in February.
$^STI
Asia
Clarity Pharmaceuticals to Start Registrational Phase 3 Trial in Neuroendocrine Tumors After US FDA Meeting
Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.The company plans to recruit around 70 participants for the trial.Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.
$ASX:CU6